Yayi Zhao

Yayi Zhao

Auto-generated profile, based on publicly available information

Yayi Zhao

Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in BJR|Artificial Intelligence
Verified
Journal Article
Open access
MZMd Muntasir Zitu
Md Muntasir Zitu
TLTuan Dung Le
Tuan Dung Le
TDThanh Duong
Thanh Duong
SHShohreh Haddadan
Shohreh Haddadan
MGMelany Garcia
Melany Garcia
TTThanh Thieu
Thanh Thieu
This review examines the use of large language models (LLMs) in cancer, analysing articles sourced from PubMed, Embase, and Ovid Medline, published between 2017 and 2024. Our search strategy included terms related to LLMs, cancer research, risks, safeguards, and ethical issues, focusing on studies that utilized text-based data. 59 articles were included in the review, categorized into 3 segments: quantitative studies on LLMs, chatbot-focused studies, and qualitative discussions on LLMs on cancer. Quantitative studies highlight LLMs’ advanced capabilities in natural language processing (NLP), while chatbot-focused articles demonstrate their potential in clinical support and data management. Qualitative research underscores the broader implications of LLMs, including the risks and ethical considerations. Our findings suggest that LLMs, notably ChatGPT, have potential in data analysis, patient interaction, and personalized treatment in cancer care. However, the review identifies critical risks, including data biases and ethical challenges. We emphasize the need for regulatory oversight, targeted model development, and continuous evaluation. In conclusion, integrating LLMs in cancer research offers promising prospects but necessitates a balanced approach focusing on accuracy, ethical integrity, and data privacy. This review underscores the need for further study, encouraging responsible exploration and application of artificial intelligence in oncology.

1 December 2018 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
RHRebecca S. Hesterberg
Rebecca S. Hesterberg
RARossybelle P Amorrortu
Rossybelle P Amorrortu
YZYayi Zhao
Yayi Zhao
SHShalaka Hampras
Shalaka Hampras
AAAfua A. Akuffo
Afua A. Akuffo
DRDana E. Rollison
Dana E. Rollison
UV radiation (UVR) causing DNA damage is a well-documented risk factor for nonmelanoma skin cancer. Although poorly understood, UVR may also indirectly contribute to carcinogenesis by promoting immune evasion. To our knowledge, we report the first epidemiological study designed to investigate the association between quantitative measures of UVR, obtained using a spectrophotometer, and circulating T regulatory (Treg) cells. In addition to total Treg cells, the proportion of functionally distinct Treg cell subsets defined by CD45RA and CD27 phenotypic markers, graded expression of FOXP3 and CD25, and those expressing cutaneous lymphocyte–associated Ag and the chemokine receptor CCR4 were enumerated in 350 individuals undergoing routine skin cancer screening exams and determined not to have prevalent skin cancer. No associations were identified for UVR exposure or the overall proportion of circulating Treg cells; however, Treg cell subpopulations with an activation-associated phenotype, CD45RA−/CD27−, and those expressing cutaneous homing receptors were significantly positively associated with UVR. These subpopulations of Treg cells also differed by age, sex, and race. After stratification by natural skin tone, and adjusting for age and sex, we found that spectrophotometer-based measures of UVR exposure, but not self-reported measures of past sun exposure, were positively correlated with the highest levels of these Treg cell subpopulations, particularly among lighter-skinned individuals. Findings from this large epidemiologic study highlight the diversity of human Treg cell subpopulations associated with UVR, thus raising questions about the specific coordinated expression of CD45RA, CD27, CCR4, and cutaneous lymphocyte–associated Ag on Treg cells and the possibility that UVR contributes to nonmelanoma skin cancer carcinogenesis through Treg cell–mediated immune evasion.

21 September 2023 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
RARossybelle P Amorrortu
Rossybelle P Amorrortu
MGMelany Garcia
Melany Garcia
YZYayi Zhao
Yayi Zhao
Issam El NaqaIssam El Naqa
Issam El Naqa
YBYoganand Balagurunathan
Yoganand Balagurunathan
DRDana E Rollison
Dana E Rollison
Background: Randomized clinical trials of novel treatments for solid tumors normally measure disease progression using the Response Evaluation Criteria in Solid Tumors. However, novel, scalable approaches to estimate disease progression using real-world data are needed to advance cancer outcomes research. The purpose of this narrative review is to summarize examples from the existing literature on approaches to estimate real-world disease progression and their relative strengths and limitations, using lung cancer as a case study.Methods: A narrative literature review was conducted in PubMed to identify articles that used approaches to estimate real-world disease progression in lung cancer patients. Data abstracted included data source, approach used to estimate real-world progression, and comparison to a selected gold standard (if applicable).Results: A total of 40 articles were identified from 2008 to 2022. Five approaches to estimate real-world disease progression were identified including manual abstraction of medical records, natural language processing of clinical notes and/or radiology reports, treatment-based algorithms, changes in tumor volume, and delta radiomics–based approaches. The accuracy of these progression approaches were assessed using different methods, including correlations between real-world endpoints and overall survival for manual abstraction (Spearman rank ρ = 0.61-0.84) and area under the curve for natural language processing approaches (area under the curve = 0.86-0.96).Conclusions: Real-world disease progression has been measured in several observational studies of lung cancer. However, comparing the accuracy of methods across studies is challenging, in part, because of the lack of a gold standard and the different methods used to evaluate accuracy. Concerted efforts are needed to define a gold standard and quality metrics for real-world data.

27 September 2018 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
DRDana E Rollison
Dana E Rollison
MSMichael J Schell
Michael J Schell
NFNeil A Fenske
Neil A Fenske
BCBasil Cherpelis
Basil Cherpelis
JMJane L Messina
Jane L Messina
MTMassimo Tommasino
Massimo Tommasino
Findings from previous studies of cutaneous human papillomavirus (cuHPV) infection and keratinocyte carcinomas (KC) have varied due to several factors, including use of different sample types for cuHPV DNA detection. Elucidating the relationship between cuHPV infection in eyebrow hairs (EBH) and skin swabs (SSW) is critical for advancing the design of future studies. DNA corresponding to 46 beta and 52 gamma cuHPV types was measured in EBH and SSW obtained from 370 individuals undergoing routine skin cancer screening exams. Prevalence of beta/gamma cuHPV was 92%/84% and 73%/43% in SSW and EBH, respectively, with 71%/39% of patients testing positive for beta/gamma cuHPV in both sample types. Number of cuHPV types detected and degree of infection were correlated across SSW and EBH. When the EBH was positive for a given beta/gamma HPV type, the SSW was positive for that same type 81%/72% of the time. Testing SSW captures more cuHPV infection than EBH, with EBH infections usually representing a subset of SSW infections. The importance of optimizing sensitivity of cuHPV infection detection using SSW versus specificity using EBH (or a combination of the two) will be ascertained in an ongoing cohort study investigating cuHPV associations with subsequent KC.

18 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
DRDana E. Rollison
Dana E. Rollison
BGBrian D. Gonzalez
Brian D. Gonzalez
KTKea L. Turner
Kea L. Turner
HJHeather S. L. Jim
Heather S. L. Jim
YZYayi Zhao
Yayi Zhao
SGScott M. Gilbert
Scott M. Gilbert
Background: Patient‐reported data can improve quality of healthcare delivery and patient outcomes. Moffitt Cancer Center (“Moffitt”) administers the Electronic Patient Questionnaire (EPQ) to collect data on demographics, including sexual orientation and gender identity (SOGI), medical history, cancer risk factors, and quality of life. Here we investigated differences in EPQ completion by demographic and cancer characteristics.Methods: An analysis including 146,142 new adult patients at Moffitt in 2009–2020 was conducted using scheduling, EPQ and cancer registry data. EPQ completion was described by calendar year and demographics. Logistic regression was used to estimate associations between demographic/cancer characteristics and EPQ completion. More recently collected information on SOGI were described.Results: Patient portal usage (81%) and EPQ completion rates (79%) were consistently high since 2014. Among patients in the cancer registry, females were more likely to complete the EPQ than males (odds ratio [OR] = 1.17, 95% confidence interval [CI] = 1.14–1.20). Patients ages 18–64 years were more likely to complete the EPQ than patients aged ≥65. Lower EPQ completion rates were observed among Black or African American patients (OR = 0.59, 95% CI = 0.56–0.63) as compared to Whites and among patients whose preferred language was Spanish (OR = 0.40, 95% CI = 0.36–0.44) or another language as compared to English. Furthermore, patients with localized (OR = 1.16, 95% CI = 1.12–1.19) or regional (OR = 1.16, 95% CI = 1.12–1.20) cancer were more likely to complete the EPQ compared to those with metastatic disease. Less than 3% of patients self‐identified as being lesbian, gay, or bisexual and <0.1% self‐identified as transgender, genderqueer, or other.Conclusions: EPQ completion rates differed across demographics highlighting opportunities for targeted process improvement. Healthcare organizations should evaluate data acquisition methods to identify potential disparities in data completeness that can impact quality of clinical care and generalizability of self‐reported data.

28 April 2023 in Cancer Medicine
Verified
Journal Article
Open access
KKKedar Shirish Kirtane
Kedar Shirish Kirtane
YZYayi Zhao
Yayi Zhao
RARossybelle P Amorrortu
Rossybelle P Amorrortu
LFLindsay Fuzzell
Lindsay Fuzzell
SVSusan Vadaparampil
Susan Vadaparampil
DRDana E. Rollison
Dana E. Rollison
Background: National Cancer Institute cancer centers (NCICCs) provide specialized cancer care including precision oncology and clinical treatment trials. While these centers can offer novel therapeutic options, less is known about when patients access these centers or at what timepoint in their disease course they receive specialized care. This is especially important since precision diagnostics and receipt of the optimal therapy upfront can impact patient outcomes and previous research suggests that access to these centers may vary by demographic characteristics. Here, we examine the timing of patients' presentation at Moffitt Cancer Center (MCC) relative to their initial diagnosis across several demographic characteristics.Methods: A retrospective cohort study was conducted among patients who presented to MCC with breast, colon, lung, melanoma, and prostate cancers between December 2008 and April 2020. Patient demographic and clinical characteristics were obtained from the Moffitt Cancer Registry. The association between patient characteristics and the timing of patient presentation to MCC relative to the patient's cancer diagnosis was examined using logistic regression.Results: Black patients (median days = 510) had a longer time between diagnosis and presentation to MCC compared to Whites (median days = 368). Black patients were also more likely to have received their initial cancer care outside of MCC compared to White patients (odds ratio [OR] and 95% confidence interval [CI] = 1.45 [1.32–1.60]). Furthermore, Hispanics were more likely to present to MCC at an advanced stage compared to non‐Hispanic patients (OR [95% CI] = 1.28 [1.05–1.55]).Conclusions: We observed racial and ethnic differences in timing of receipt of care at MCC. Future studies should aim to identify contributing factors for the development of novel mitigation strategies and assess whether timing differences in referral to an NCICC correlate with long‐term patient outcomes.